| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate |
2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50f31eba7456acce22019d533f71aef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12bca213624cc6b0a62509e8997b9fec |
| publicationDate |
2019-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019004415-A1 |
| titleOfInvention |
METHOD FOR PREDICTING THE EFFECT OF ANTITUMOR IMMUNOTHERAPY USING PERIPHERAL BLOOD TUMOR CYTOTOXIC ACTIVITY AS INDEX |
| abstract |
The problem described by the present invention is to provide a companion diagnosis for predicting the effect of antitumor immunotherapy. The effect of antitumor immunotherapy is predicted by a method comprising: step 1 for directly or indirectly contacting tumor cells in vitro with peripheral blood mononuclear cells, said cells being collected from a patient to be undergoing treatment for a malignant tumor; step 2 to determine if the tumor cells, which have been contacted with the peripheral blood mononuclear cells in step 1, are damaged; and step 3 for, when the tumor cells are considered damaged in step 2, then judging that antitumor immunotherapy is effective against the patient's malignancy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679128-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10716809-B2 |
| priorityDate |
2017-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |